お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:抗肥満薬の世界市場:成長、動向、予測(2019~2024年)
市場調査レポート
商品コード
391328

抗肥満薬の世界市場:成長、動向、予測(2019~2024年)

Anti-obesity Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
抗肥満薬の世界市場:成長、動向、予測(2019~2024年)
出版日: 2021年02月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の抗肥満薬市場は、米国FDAや欧州EMAからの認可数の増加に伴い、着実に成長しています。2012年から2016年にかけ、多くの製薬会社が治験に多額の投資を行ないました。

当レポートでは、世界の抗肥満薬市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場の定義動向

  • 市場概要
  • 市場促進因子
    • 肥満罹患率上昇
    • 座りっぱなしの生活習慣
  • 市場阻害因子
    • 代替治療法の入手性
    • 薬剤の副作用
    • 高い薬剤開発コスト
  • 業界の魅力度:ポーターズファイブフォース分析

第5章 市場セグメンテーション

  • 作用機序別
    • 抹消作用抗肥満薬
    • 中枢作用性抗肥満薬
  • 薬剤別
    • 処方薬
    • OTC薬
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合環境

  • 企業プロファイル
    • Arena Pharmaceuticals
    • GlaxoSmithKline
    • Nalpropion Pharmaceuticals Inc.
    • F Hoffmann-La Roche
    • Vivus
    • Bayer AG
    • Novo Nordisk
    • Pfizer
    • エーザイ株式会社

第7章 市場の機会と将来動向

目次
Product Code: 53633

The global anti-obesity drugs market was valued at about USD 1,690 million in 2020 and is expected to reach USD 4,250 million in 2026, by registering a CAGR of 15% over the forecast period.

In the current COVID-19 situation it was also observed that obesity has increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The major reason being a change in lifestyle and a decrease in exercise practice in the population owing to the avoidance of gyming and yoga classes by the majority of the population due to the current social distancing protocols and. This increase in the obesity population is expected to increase the demand for anti-obesity drugs in near future.

According to a report published by Our World In Data in 2017, 13% of adults in the world are obese and 39% of all adults in the world are overweight. Each one-in-five children and adolescents, globally, are overweight. Incidences of obesity is increasing fiercely over the past decades and it is often described as a global endemic, especially in the developed countries where lifestyle associated disorders such as anxiety, stress, smoking, drinking are more prevalent.

Owing to the increase in the obesity population worldwide, the key players in the market are also undergoing product development and seeking market approvals. For instance, in 2018, a Danish pharma company Novo Nordisk entered into a strategic partnership with Evotec AG to discover and develop drug molecules to treat several metabolic disorders including obesity, diabetes, and other associated disorders. Later on In December 2020, Novo Nordisk submitted a marketing authorization application to the European Medicines Agency (EMA), seeking approval for a once-weekly semaglutide for weight management.

In addition, research on several potential drug molecules that target both obesity and type 2 diabetes mellitus has become a key trend in the anti-obesity market players. The increasing epidemic of obesity and type 2 diabetes is encouraging researchers and vendors in the market to research drugs that can counter both obesity and type 2 diabetes. Hence, the increasing obesity population along with an increase in unhealthy eating habits and a sedentary lifestyle is expected to drive market growth over the forecast period.

However, the availability of alternative therapies and the potential side-effects caused by the anti-obesity drugs are expected to restraint market growth.

Key Market Trends

Prescription Drugs Segment is Expected to Exhibit a Better Growth Rate over the Forecast Period

By Drug Type, the Prescription Drug segment is expected to hold a significant market share. In the current COVID-19 scenario, various companies are exploring the new class of medicines that helps people lose weight and control diabetes as a potential in fighting pandemic disease. As COVID-19 has seen severe consequences in the obese population. In September 2020, Novo Nordisk A/S, that they are performing research on GLP-1 drug used for obesity in COVID-19 patients. These research and development activities in the future are expected to propel the demand for prescription drugs. Moreover, the rising intake of junk foods/fast foods is resulting in declining health among the population, worldwide. and leading to an increase in the prevalence of obesity, especially in some developed parts of the world. For instance, in the United States, from 1999-2000 to 2017-2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%, as per the 2018 report by the Centers for Disease Control and Prevention.

In June 2020, China Medical System Holdings signed a USD 400 million-plus agreement for Chinese commercialization rights to US biotech Gelesis Inc.'s prescription obesity management product Plenty. All these development by the players coupled with increasing awareness of prescription medicine is anticipated to boost the growth of the prescription drug segment.

North America is Expected to Dominate the Market over the Forecast Period

North America is expected to dominate the global anti-obesity drugs market, The primary factors driving the growth of the market studied are an increase in the obese population and high healthcare spending.

In September 2020, The Centers for Disease Control and Prevention (CDC) notified that adult obesity prevalence is increasing and racial and ethnic disparities persist owing to the current circumstances of work from home, less physical activities, financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 % including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia which is much high as compared to 2018 where 9 states reported 35% obese population.

Also, according to the finding of CDC in 2017-18, the age-adjusted prevalence of obesity in adults was 42.4%, and there were no significant differences between men and women among all adults or by age group. Also, as per the data published by Organisation for EconomicCo-operation and Development, in Canada 59.1% of the population aged 15 years or more was obese whereas in Mexico, 75.2% of the population aged 15 years or more was obese 2017- 2018.

The high obesity rate has always attracted the key players to make developments in the region. For instance, in 2020, Kintai Therapeutics, a United States headquartered company, announced that they are working across therapeutic areas and is beginning IND-enabling studies for its first potential therapeutic for the treatment of obesity. The first drug candidate is KTX-0200, which has demonstrated sustained weight loss and improvements in other markers of health in animal models. The launch of these pipeline products along with the increasing geographic footprints of the player is expected to propel market growth in this region.

Competitive Landscape

The presence of major market players, such as GlaxoSmithKline PLC, Novo Nordisk AS, Pfizer Inc., F Hoffmann-La Roche AG, and Bayer AG, is increasing the overall competitive rivalry of the market. The key players are focused on inorganic growth strategies organizations such as collaborating with successful personality, initiative, or programs at the national levels, which promote their product. Therefore, these are recognized earlier than other brands in the market studied. With the high prevalence rate of the disease, the intensity of competitive rivalry is moderate to high.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Obesity and Related Chronic Diseases
    • 4.2.2 Growing Unhealthy and Sedentary Lifestyle
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatment Options
    • 4.3.2 Side Effect of Drugs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Mechanism of Action
    • 5.1.1 Peripherally Acting Drugs
    • 5.1.2 Centrally Acting Drugs
  • 5.2 By Drug Type
    • 5.2.1 Prescription Drugs
    • 5.2.2 OTC Drugs
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (By Mechanism of Action and By Drug Type)
      • 5.3.1.2 Canada (By Mechanism of Action and By Drug Type)
      • 5.3.1.3 Mexico (By Mechanism of Action and By Drug Type)
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom (By Mechanism of Action and By Drug Type)
      • 5.3.2.2 Germany (By Mechanism of Action and By Drug Type)
      • 5.3.2.3 France (By Mechanism of Action and By Drug Type)
      • 5.3.2.4 Italy (By Mechanism of Action and By Drug Type)
      • 5.3.2.5 Spain (By Mechanism of Action and By Drug Type)
      • 5.3.2.6 Rest of Europe (By Mechanism of Action and By Drug Type)
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China (By Mechanism of Action and By Drug Type)
      • 5.3.3.2 Japan (By Mechanism of Action and By Drug Type)
      • 5.3.3.3 India (By Mechanism of Action and By Drug Type)
      • 5.3.3.4 Australia (By Mechanism of Action and By Drug Type)
      • 5.3.3.5 South Korea (By Mechanism of Action and By Drug Type)
      • 5.3.3.6 Rest of Asia-Pacific (By Mechanism of Action and By Drug Type)
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC (By Mechanism of Action and By Drug Type)
      • 5.3.4.2 South Africa (By Mechanism of Action and By Drug Type)
      • 5.3.4.3 Rest of Middle East and Africa (By Mechanism of Action and By Drug Type)
    • 5.3.5 South America
      • 5.3.5.1 Brazil (By Mechanism of Action and By Drug Type)
      • 5.3.5.2 Argentina (By Mechanism of Action and By Drug Type)
      • 5.3.5.3 Rest of South America (By Mechanism of Action and By Drug Type)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arena Pharmaceuticals, Inc.,
    • 6.1.2 Alizyme
    • 6.1.3 Bayer AG
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 Currax Pharmaceuticals LLC
    • 6.1.6 Eisai, Co. Ltd
    • 6.1.7 F. Hoffmann-La Roche AG
    • 6.1.8 GlaxoSmithKline PLC
    • 6.1.9 Merck & Co. Inc.
    • 6.1.10 Norgine B.V.
    • 6.1.11 Novo Nordisk AS

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.